X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

August 14, 2020

How the FDA PFDD initiative is bringing the patients voice earlier into drug development

In the biologics space, there are clear trends toward higher delivery volumes, less frequent dosing, and the conversion from intravenous to subcutaneous delivery. This is driving demand for wearable technologies. Read more below about the FDA’s Patient-Focused Drug Development (PFDD) Initiative and how these findings can enable more insightful patient offerings.
Victoria Morgan

Victoria Morgan

Global Director, Segment Marketing

Categories

Search the Blog

Archive

{1}

{2}
{3}

{4}